The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosi...
Where can researchers look for a beacon of hope amid trying times in the pharmac...
This study reinforces the significance of intensive glycaemic control and is a p...
GSK and the University of Oxford have entered a new research partnership to laun...
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaur...
If approved, Welireg would be the only available therapy in the US for eligible ...
With continued investment and growing buzz from the industry, the AI hype is exp...
Tevogen Bio has expanded its partnership with Microsoft, aiming to further their...
The UK biotech sector raised £3.5bn in 2024, the highest annual total since 2021...
The funds will support the development of Ascentage’s pipeline, including its le...
The settlement ends the Sackler family’s ownership of the Oxycontin developer Pu...
The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Ta...
Adaptive logistics are vital for clinical trials, but there are challenges in na...
The FDA rejected the company’s initial NDA in 2021, citing the lack of an adequa...
Disc Medicine finalised the pivotal Phase III trial design of bitopertin in eryt...
The FDA reported that six patients died after being injected with Teva’s Copaxon...
